NeuroThera expanded its collaboration with Clearmind Medicine to build U.S. patent coverage for PEA combinations with psychedelic-derived compounds.
Three published U.S. patent applications cover PEA used with LSD, ketamine, or ibogaine for potential mental health, pain, or substance use indications.
The work follows an earlier U.S. patent application from the collaboration covering an MDMA-PEA combination targeting PTSD, anxiety, or eating disorders.
CMND•
